1
|
Peterson C, Toll SA, Kolb B, Poulik JM, Reyes-Mugica M, Sood S, Haridas A, Wang ZJ, Marupudi NI. Novel Finding of Copy Number Gains in GNAS and Loss of 10q in a Child With Malignant Transformation of Neurocutaneous Melanosis Syndrome. JCO Precis Oncol 2022; 5:33-38. [PMID: 34994589 DOI: 10.1200/po.20.00244] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Affiliation(s)
- Catherine Peterson
- Department of Neurosurgery, Detroit Medical Center, Detroit, MI.,Wayne State University School of Medicine, Detroit, MI
| | - Stephanie A Toll
- Department of Pediatrics, Division of Hematology/Oncology, Children's Hospital of Michigan, Detroit, MI
| | - Bradley Kolb
- Wayne State University School of Medicine, Detroit, MI
| | - Janet M Poulik
- Department of Pathology, Wayne State University, Detroit, MI
| | | | - Sandeep Sood
- Department of Neurosurgery, Detroit Medical Center, Detroit, MI.,Wayne State University School of Medicine, Detroit, MI.,Department of Pediatric Neurosurgery, Children's Hospital of Michigan, Detroit, MI
| | - Abilash Haridas
- Department of Neurosurgery, Detroit Medical Center, Detroit, MI.,Wayne State University School of Medicine, Detroit, MI.,Department of Pediatric Neurosurgery, Children's Hospital of Michigan, Detroit, MI
| | - Zhihong Joanne Wang
- Wayne State University School of Medicine, Detroit, MI.,Department of Pediatrics, Division of Hematology/Oncology, Children's Hospital of Michigan, Detroit, MI
| | - Neena I Marupudi
- Department of Neurosurgery, Detroit Medical Center, Detroit, MI.,Wayne State University School of Medicine, Detroit, MI.,Department of Pediatric Neurosurgery, Children's Hospital of Michigan, Detroit, MI
| |
Collapse
|
2
|
Jain M, Tran S, Thakur S, Nagashima Y, Anderson R, Narendran A. Lin28A/ let-7 oncogenic circuit is a potential therapeutic target in neurocutaneous melanosis-associated CNS tumors in children. Neurooncol Adv 2020; 3:vdaa174. [PMID: 33506207 PMCID: PMC7813159 DOI: 10.1093/noajnl/vdaa174] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Affiliation(s)
- Mohit Jain
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.,Department Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Son Tran
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.,Department Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Satbir Thakur
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.,Department Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Yoji Nagashima
- Department of Surgical Pathology, Tokyo Women's Medical University Hospital, Tokyo, Japan
| | - Ronald Anderson
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.,Department Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Aru Narendran
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.,Department Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| |
Collapse
|
3
|
Vanood A, Lee YA, Leleszi E, Krishnan A. Symptomatic neurocutaneous melanosis: mild clinical onset in a teenager. BMJ Case Rep 2020; 13:13/11/e235772. [PMID: 33257354 DOI: 10.1136/bcr-2020-235772] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Neurocutaneous melanosis (NCM) is a rare disorder characterised by giant or multiple melanocytic nevi and meningeal melanosis or melanoma. Onset of neurological symptoms is typically in children younger than 2 years and can be rapidly fatal. We present the case of a 13-year-old adopted girl presenting with numerous congenital melanocytic nevi and a seizure. She had no significant previous neurological history. Electroencephalogram showed epileptiform discharges over the right frontal region. MRI of the brain showed T1 hyperintensity in the bilateral amygdala and anterior temporal lobes with corresponding hyperintensity on T2 and fluid attenuated inversion recovery. There was no hydrocephalus. Along with the history of nevi, these imaging findings were concerning for NCM. The patient is being managed with levetiracetam and trametinib and shows no further neurological decline at 1-year follow-up, providing prognostic hope in this case of NCM.
Collapse
Affiliation(s)
- Aimen Vanood
- Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA
| | - Young Ah Lee
- Department of Pediatrics, Banner Desert Medical Center, Mesa, Arizona, USA
| | - Elizabeth Leleszi
- Department of Pediatrics, Beaumont Children's Hospital, Royal Oak, Michigan, USA
| | - Anant Krishnan
- Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA .,Department of Diagnostic Radiology and Molecular Imaging, Beaumont Hospital, Royal Oak, Michigan, USA
| |
Collapse
|
4
|
Ruggieri M, Polizzi A, Catanzaro S, Bianco ML, Praticò AD, Di Rocco C. Neurocutaneous melanocytosis (melanosis). Childs Nerv Syst 2020; 36:2571-2596. [PMID: 33048248 DOI: 10.1007/s00381-020-04770-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Accepted: 06/23/2020] [Indexed: 02/03/2023]
Abstract
Neurocutaneous melanosis (NCM; MIM # 249400; ORPHA: 2481], first reported by the Bohemian pathologist Rokitansky in 1861, and now more precisely defined as neurocutaneous melanocytosis, is a rare, congenital syndrome characterised by the association of (1) congenital melanocytic nevi (CMN) of the skin with overlying hypertrichosis, presenting as (a) large (LCMN) or giant and/or multiple (MCMN) melanocytic lesions (or both; sometimes associated with smaller "satellite" nevi) or (b) as proliferative melanocytic nodules; and (2) melanocytosis (with infiltration) of the brain parenchyma and/or leptomeninges. CMN of the skin and leptomeningeal/nervous system infiltration are usually benign, more rarely may progress to melanoma or non-malignant melanosis of the brain. Approximately 12% of individuals with LCMN will develop NCM: wide extension and/or dorsal axial distribution of LCMN increases the risk of NCM. The CMN are recognised at birth and are distributed over the skin according to 6 or more patterns (6B patterns) in line with the archetypical patterns of distribution of mosaic skin disorders. Neurological manifestations can appear acutely in infancy, or more frequently later in childhood or adult life, and include signs/symptoms of intracranial hypertension, seizures/epilepsy, cranial nerve palsies, motor/sensory deficits, cognitive/behavioural abnormalities, sleep cycle anomalies, and eventually neurological deterioration. NMC patients may be symptomatic or asymptomatic, with or without evidence of the typical nervous system changes at MRI. Associated brain and spinal cord malformations include the Dandy-Walker malformation (DWM) complex, hemimegalencephaly, cortical dysplasia, arachnoid cysts, Chiari I and II malformations, syringomyelia, meningoceles, occult spinal dysraphism, and CNS lipoma/lipomatosis. There is no systemic involvement, or only rarely. Pathogenically, single postzygotic mutations in the NRAS (neuroblastoma RAS viral oncogene homologue; MIM # 164790; at 1p13.2) proto-oncogene explain the occurrence of single/multiple CMNs and melanocytic and non-melanocytic nervous system lesions in NCM: these disrupt the RAS/ERK/mTOR/PI3K/akt pathways. Diagnostic/surveillance work-ups require physical examination, ophthalmoscopy, brain/spinal cord magnetic resonance imaging (MRI) and angiography (MRA), positron emission tomography (PET), and video-EEG and IQ testing. Treatment strategies include laser therapy, chemical peeling, dermabrasion, and surgical removal/grafting for CMNs and shunt surgery and surgical removal/chemo/radiotherapy for CNS lesions. Biologically targeted therapies tailored (a) BRAF/MEK in NCM mice (MEK162) and GCMN (trametinib); (b) PI3K/mTOR (omipalisib/GSK2126458) in NMC cells; (c) RAS/MEK (vemurafenib and trametinib) in LCMNs cells; or created experimental NMC cells (YP-MEL).
Collapse
Affiliation(s)
- Martino Ruggieri
- Unit of Rare Diseases of the Nervous System in Childhood, Department of Clinical and Experimental Medicine, Section of Pediatrics and Child Neuropsychiatry, University of Catania, Catania, Italy.
| | - Agata Polizzi
- Chair of Pediatrics, Department of Educational Sciences, University of Catania, Catania, Italy
| | - Stefano Catanzaro
- Unit of Rare Diseases of the Nervous System in Childhood, Department of Clinical and Experimental Medicine, Section of Pediatrics and Child Neuropsychiatry, University of Catania, Catania, Italy
- Unit of Neonatology and Neonatal Intensive Care Unit (NICU), AOU "Policlinico", PO "San Marco", University of Catania, Catania, Italy
| | - Manuela Lo Bianco
- Postgraduate Programme in Pediatrics, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
| | - Andrea D Praticò
- Unit of Rare Diseases of the Nervous System in Childhood, Department of Clinical and Experimental Medicine, Section of Pediatrics and Child Neuropsychiatry, University of Catania, Catania, Italy
| | - Concezio Di Rocco
- Pediatric Neurosurgery, International Neuroscience Institute (INI), Hannover, Germany
| |
Collapse
|
5
|
Basu D, Salgado CM, Bauer B, Khakoo Y, Patel JR, Hoehl RM, Bertolini DM, Zabec J, Brzozowski MR, Reyes-Múgica M. The Dual PI3K/mToR Inhibitor Omipalisib/GSK2126458 Inhibits Clonogenic Growth in Oncogenically-transformed Cells from Neurocutaneous Melanocytosis. Cancer Genomics Proteomics 2018; 15:239-248. [PMID: 29976629 DOI: 10.21873/cgp.20082] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2018] [Revised: 06/01/2018] [Accepted: 06/06/2018] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Omipalisib has been found to affect the viability of cancer cells. However, its effect on clonogenicity - a feature of cancer stem cells, is not clear. Cells isolated from neurocutaneous melanocytosis (NCM) patients' lesions grow clonogenically. The aim of this study was to investigate the effect of omipalisib treatment on clonogenic growth of NCM cells in vitro. MATERIALS AND METHODS Clonogenic growth efficiency was evaluated by colony formation assays with or without specific growth factors. Activation of MEK and Akt was determined by immunoblots. Colony formation and cell viability were assessed upon pharmacological inhibition of MEK, Akt and mToR. RESULTS Clonogenicity appeared to depend on bFGF and IGF1signaling through ERK and Akt. Omipalisib treatment prevented colony formation and induced autophagic cell death. CONCLUSION Signaling through Akt is important for survival of clonogenic cells in NCM, and omipalisib treatment as a monotherapy or in combination with MEK162 could be an effective therapeutic strategy to inhibit clonogenic growth.
Collapse
Affiliation(s)
- Dipanjan Basu
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, PA, U.S.A
| | - Cláudia M Salgado
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, PA, U.S.A
| | - Bruce Bauer
- Division of Plastic and Reconstructive Surgery, North Shore University Health System, Northbrook, IL, U.S.A
| | - Yasmin Khakoo
- Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, U.S.A.,Department of Pediatrics, Weill Cornell Medical College, New York, NY, U.S.A
| | - Janki R Patel
- Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, PA, U.S.A
| | - Ryan M Hoehl
- Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, PA, U.S.A
| | - Dominique M Bertolini
- Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, PA, U.S.A
| | - Joie Zabec
- Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, PA, U.S.A
| | - Morgan R Brzozowski
- Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, PA, U.S.A
| | - Miguel Reyes-Múgica
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, PA, U.S.A
| |
Collapse
|
6
|
Habougit C, Forest F, Boutet C, Douchet C, Stephan JL, Stachowicz ML, Vassal F, Péoc'h M. AN 11-Year-Old Boy with a Leptomeningeal Tumor. Brain Pathol 2018; 27:553-554. [PMID: 28585389 DOI: 10.1111/bpa.12527] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Affiliation(s)
- Cyril Habougit
- Department of Pathology, North Hospital, Avenue Albert Raimond, 42055 Saint Etienne CEDEX 2, France
| | - Fabien Forest
- Department of Pathology, North Hospital, Avenue Albert Raimond, 42055 Saint Etienne CEDEX 2, France
| | - Claire Boutet
- Department of Radiology, North Hospital, Avenue Albert Raimond, 42055 Saint Etienne CEDEX 2, France
| | - Catherine Douchet
- Department of Pathology, North Hospital, Avenue Albert Raimond, 42055 Saint Etienne CEDEX 2, France
| | - Jean-Louis Stephan
- Department of Pediatric Oncology, North Hospital, Avenue Albert Raimond, 42055 Saint Etienne CEDEX 2, France
| | - Marie-Laure Stachowicz
- Department of Pathology, North Hospital, Avenue Albert Raimond, 42055 Saint Etienne CEDEX 2, France
| | - Francois Vassal
- Department of Neurosurgery of Saint Etienne University Hospital, North Hospital, Avenue Albert Raimond, 42055 Saint Etienne CEDEX 2, France
| | - Michel Péoc'h
- Department of Pathology, North Hospital, Avenue Albert Raimond, 42055 Saint Etienne CEDEX 2, France
| |
Collapse
|
7
|
NRAS(Q61K) mutated primary leptomeningeal melanoma in a child: case presentation and discussion on clinical and diagnostic implications. BMC Cancer 2016; 16:512. [PMID: 27439913 PMCID: PMC4955223 DOI: 10.1186/s12885-016-2556-y] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2016] [Accepted: 07/13/2016] [Indexed: 11/10/2022] Open
Abstract
Background Primary melanocytic neoplasms are rare in the pediatric age. Among them, the pattern of neoplastic meningitis represents a peculiar diagnostic challenge since neuroradiological features may be subtle and cerebrospinal fluid analysis may not be informative. Clinical misdiagnosis of neoplastic meningitis with tuberculous meningitis has been described in few pediatric cases, leading to a significant delay in appropriate management of patients. We describe the case of a child with primary leptomeningeal melanoma (LMM) that was initially misdiagnosed with tuberculous meningitis. We review the clinical and molecular aspects of LMM and discuss on clinical and diagnostic implications. Case presentation A 27-month-old girl with a 1-week history of vomiting with mild intermittent strabismus underwent Magnetic Resonance Imaging, showing diffuse brainstem and spinal leptomeningeal enhancement. Cerebrospinal fluid analysis was unremarkable. Antitubercular treatment was started without any improvement. A spinal intradural biopsy was suggestive for primary leptomeningeal melanomatosis. Chemotherapy was started, but general clinical conditions progressively worsened and patient died 11 months after diagnosis. Molecular investigations were performed post-mortem on tumor tissue and revealed absence of BRAFV600E, GNAQQ209 and GNA11Q209 mutations but the presence of a NRASQ61K mutation. Conclusions Our case adds some information to the limited experience of the literature, confirming the presence of the NRASQ61K mutation in children with melanomatosis. To our knowledge, this is the first case of leptomeningeal melanocytic neoplasms (LMN) without associated skin lesions to harbor this mutation. Isolated LMN presentation might be insidious, mimicking tuberculous meningitis, and should be suspected if no definite diagnosis is possible or if antitubercular treatment does not result in dramatic clinical improvement. Leptomeningeal biopsy should be considered, not only to confirm diagnosis of LMN but also to study molecular profile. Further molecular profiling and preclinical models will be pivotal in testing combination of target therapy to treat this challenging disease.
Collapse
|
8
|
Ruan Y, Narendran A. Response to "Insulin-like growth factor 1 receptor signaling via Akt: a general therapeutic target in neurocutaneous melanocytosis?". Neuro Oncol 2015; 18:143-4. [PMID: 26667140 DOI: 10.1093/neuonc/nov290] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Affiliation(s)
- Yibing Ruan
- Division of Pediatric Oncology, Alberta Children's Hospital and POETIC Laboratory for Preclinical and Drug Discovery Studies, University of Calgary, Calgary, Alberta, Canada
| | - Aru Narendran
- Division of Pediatric Oncology, Alberta Children's Hospital and POETIC Laboratory for Preclinical and Drug Discovery Studies, University of Calgary, Calgary, Alberta, Canada
| |
Collapse
|
9
|
Patel J, Salgado CM, Múgica MR, Basu D. Insulin-like growth factor 1 receptor signaling via Akt: a general therapeutic target in neurocutaneous melanocytosis? Neuro Oncol 2015; 18:142-3. [PMID: 26667139 DOI: 10.1093/neuonc/nov271] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Janki Patel
- Department of Pathology, Children's Hospital of Pittsburgh of UPMC and Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Cláudia M Salgado
- Department of Pathology, Children's Hospital of Pittsburgh of UPMC and Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Miguel Reyes Múgica
- Department of Pathology, Children's Hospital of Pittsburgh of UPMC and Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Dipanjan Basu
- Department of Pathology, Children's Hospital of Pittsburgh of UPMC and Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania
| |
Collapse
|
10
|
Küsters-Vandevelde HVN, Küsters B, van Engen-van Grunsven ACH, Groenen PJTA, Wesseling P, Blokx WAM. Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects. Brain Pathol 2015; 25:209-26. [PMID: 25534128 DOI: 10.1111/bpa.12241] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2014] [Accepted: 12/16/2014] [Indexed: 02/06/2023] Open
Abstract
Primary melanocytic tumors of the central nervous system (CNS) represent a spectrum of rare tumors. They can be benign or malignant and occur in adults as well as in children, the latter often in the context of neurocutaneous melanosis. Until recently, the genetic alterations in these tumors were largely unknown. This is in contrast with cutaneous and uveal melanomas, which are known to harbor distinct oncogenic mutations that can be used as targets for treatment with small-molecule inhibitors in the advanced setting. Recently, novel insights in the molecular alterations underlying primary melanocytic tumors of the CNS were obtained, including different oncogenic mutations in tumors in adult patients (especially GNAQ, GNA11) vs. children (especially NRAS). In this review, the focus is on molecular characteristics of primary melanocytic tumors of the CNS. We summarize what is known about their genetic alterations and discuss implications for pathogenesis and differential diagnosis with other pigmented tumors in or around the CNS. Finally, new therapeutic options with targeted therapy are discussed.
Collapse
|
11
|
Basu D, Salgado CM, Bauer BS, Johnson D, Rundell V, Nikiforova M, Khakoo Y, Gunwaldt LJ, Panigrahy A, Reyes-Múgica M. Nevospheres from neurocutaneous melanocytosis cells show reduced viability when treated with specific inhibitors of NRAS signaling pathway. Neuro Oncol 2015; 18:528-37. [PMID: 26354928 DOI: 10.1093/neuonc/nov184] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Accepted: 08/04/2015] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Neurocutaneous melanocytosis (NCM) is characterized by clonal nevomelanocytic proliferations in the CNS and skin. Given the scarcity of effective therapeutic targets, testing new drugs requires a reliable and reproducible in vitro cellular model of the disease. METHODS We generated nevomelanocytic spheroids in vitro from lesions of the spinal cord, brain, and skin from 4 NCM patients. Nevomelanocytic cells were grown as monolayers or spheroids and their growth characteristics were evaluated. Cultured cell identity was confirmed by demonstration of the same NRAS mutation found in the original lesions and by immunophenotyping. Nevomelanocytic spheroids were treated with inhibitors of specific mediators of the NRAS signaling pathway (vemurafenib, MEK162, GDC0941, and GSK2126458). Drug sensitivity and cell viability were assessed. RESULTS Cultured cells were growth-factor dependent, grew as spheroids on Geltrex matrix, and maintained their clonogenicity in vitro over passages. Skin-derived cells formed more colonies than CNS-derived cells. Inhibitors of specific mediators of the NRAS signaling pathway reduced viability of NRAS mutated cells. The highest effect was obtained with GSK2126458, showing a viability reduction below 50%. CONCLUSIONS NRAS mutated cells derived from clinical NCM samples are capable of continuous growth as spheroid colonies in vitro and retain their genetic identity. Drugs targeting the NRAS signaling pathway reduce in vitro viability of NCM cells. NCM lesional spheroids represent a new and reliable experimental model of NCM for use in drug testing and mechanistic studies.
Collapse
Affiliation(s)
- Dipanjan Basu
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| | - Cláudia M Salgado
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| | - Bruce S Bauer
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| | - Donald Johnson
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| | - Veronica Rundell
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| | - Marina Nikiforova
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| | - Yasmin Khakoo
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| | - Lorelei J Gunwaldt
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| | - Ashok Panigrahy
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| | - Miguel Reyes-Múgica
- Department of Pathology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (D.B., C.M.S., M.R.M.); Department of Plastic Surgery, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (L.J.G.); Department of Radiology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania (A.P.); Division of Plastic and Reconstructive Surgery, NorthShore University HealthSystem, Northbrook, Illinois (B.S.B., D.J., V.R.); Division of Molecular Genomic Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (M.N.); Department of Pediatrics and Neurology, Memorial Sloan Kettering Cancer Center, New York, New York (Y.K.); Department of Pediatrics, Weill Cornell Medical College, New York, New York (Y.K.)
| |
Collapse
|
12
|
Uguen A, Laurent C, Samaison L, Boisselier B, Talagas M, Costa S, Aziza J, Mokhtari K, Le Maréchal C, Marcorelles P. Severe hydrocephalus caused by diffuse leptomeningeal and neurocutaneous melanocytosis of antenatal onset: a clinical, pathologic, and molecular study of 2 cases. Hum Pathol 2015; 46:1189-96. [DOI: 10.1016/j.humpath.2015.04.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/24/2015] [Revised: 03/24/2015] [Accepted: 04/20/2015] [Indexed: 11/26/2022]
|